Biologic Therapy for HLA-B27-associated Ocular Disorders.

Area of Science:

• Immunology and Rheumatology
• Ophthalmology

Background:

• HLA-B27-associated spondyloarthropathies involve significant articular and extra-articular manifestations.
• Uveitis is the most common extra-articular feature in HLA-B27-positive patients.
• Traditional treatments include topical corticosteroids and cycloplegics, with biologics emerging for refractory cases.

Purpose of the Study:

• To review the current management of HLA-B27-associated ocular disorders.
• To update on the role of biologic agents, including anti-TNFα and non-anti-TNFα therapies.
• To explore emerging biologic targets for spondyloarthropathies and their impact on uveitis.

Main Methods:

• Literature review of biologic therapies for HLA-B27-associated uveitis.
• Analysis of data on anti-tumor necrosis factor α (anti-TNFα) agents.
• Examination of evidence for non-anti-TNFα biologics and novel agents targeting IL-12/23 and IL-17.

Main Results:

• Biologic agents, especially anti-TNFα therapies, have revolutionized treatment for HLA-B27-associated conditions.
• Biologics demonstrate efficacy in managing refractory or recurrent uveitis.
• Data on newer biologics targeting IL-12/23 and IL-17 for anterior uveitis in spondyloarthropathies is limited.

Conclusions:

• Biologic therapies, particularly anti-TNFα agents, are crucial for managing HLA-B27-associated uveitis.
• Emerging biologics offer potential but require further investigation for efficacy in ocular manifestations.
• Continued research is needed to establish the role of novel biologics in treating HLA-B27-associated ocular disorders.